{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:27:11Z","timestamp":1767961631976,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.ejca.2010.04.012","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T06:22:04Z","timestamp":1274077324000},"page":"2187-2195","source":"Crossref","is-referenced-by-count":30,"title":["Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss"],"prefix":"10.1016","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct00558272","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00559507","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00696072","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00767520","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00793546","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00880009","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stephen","family":"Hiscox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Barrett-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel C.","family":"Borley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert I.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.04.012_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","article-title":"Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers","volume":"123","author":"Nadji","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2010.04.012_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1054\/bjoc.1999.0954","article-title":"Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer","volume":"82","author":"Nicholson","year":"2000","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2010.04.012_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2009.03.006","article-title":"Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Valachis","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2010.04.012_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdm282","article-title":"The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors","volume":"19","author":"Rugo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.6004\/jnccn.2006.0082","article-title":"Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations","volume":"4","author":"Carlson","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2010.04.012_bib7","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer, V.1.2009. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf [accessed September 2009]."},{"key":"10.1016\/j.ejca.2010.04.012_bib8","unstructured":"National Institute for Health and Clinical Excellence (NICE). CG81 Advanced breast cancer: full guidance. Available at http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG81FullGuideline.pdf [accessed October 2009]."},{"key":"10.1016\/j.ejca.2010.04.012_bib9","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Saad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.04.012_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10555-006-9023-1","article-title":"Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases","volume":"25","author":"Siclari","year":"2006","journal-title":"Cancer Metast Rev"},{"key":"10.1016\/j.ejca.2010.04.012_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.186.4.489","article-title":"Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts","volume":"186","author":"Kameda","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2010.04.012_bib13","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ctrv.2008.03.005","article-title":"Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2010.04.012_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1359-6349(09)72025-7","article-title":"Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer","volume":"7","author":"van de Velde","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejca.2010.04.012_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.breast.2009.03.003","article-title":"The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial","volume":"18","author":"Hadji","year":"2009","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2010.04.012_bib16","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3816\/SCT.2007.n.003","article-title":"Treatment of bone metastases and bone pain with bisphosphonates","volume":"4","author":"Lipton","year":"2007","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.ejca.2010.04.012_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2010.04.012_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2010.04.012_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.04.012_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1359-6349(09)72028-2","article-title":"Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study","volume":"7","author":"Stopeck","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejca.2010.04.012_bib22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.onc.1204205","article-title":"Src family kinases and HER2 interactions in human breast cancer cell growth and survival","volume":"20","author":"Belsches-Jablonski","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2010.04.012_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s004320000197","article-title":"Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue","volume":"127","author":"Reissig","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib24","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr2332","article-title":"Increased levels of active c-Src distinguish invasive from in situ lobular lesions","volume":"11","author":"Zou","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.4161\/cbt.8.16.8954","article-title":"Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically","volume":"8","author":"Morgan","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2010.04.012_bib26","first-page":"2430","article-title":"Src family kinase inhibitor PP2 restores the E-cadherin\/catenin cell adhesion system in human cancer cells and reduces cancer metastasis","volume":"8","author":"Nam","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib27","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr1524","article-title":"Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial\u2013mesenchymal transition in mammary epithelial cells","volume":"8","author":"Galliher","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib28","doi-asserted-by":"crossref","first-page":"20851","DOI":"10.1074\/jbc.M601570200","article-title":"Role of c-Src in human MCF7 breast cancer cell tumorigenesis","volume":"281","author":"Gonzalez","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.04.012_bib29","first-page":"5028","article-title":"C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis","volume":"63","author":"Myoui","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib30","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2174\/1381612023393323","article-title":"Targeting protein kinases for bone disease: discovery and development of Src inhibitors","volume":"8","author":"Metcalf","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2010.04.012_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10165-006-0460-z","article-title":"The role of c-Src kinase in the regulation of osteoclast function","volume":"16","author":"Miyazaki","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ejca.2010.04.012_bib32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI116032","article-title":"Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice","volume":"90","author":"Boyce","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2010.04.012_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"Soriano","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2010.04.012_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased c-Src expression enhances osteoblast differentiation and bone formation","volume":"151","author":"Marzia","year":"2000","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ejca.2010.04.012_bib35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","article-title":"The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts","volume":"7","author":"de Vries","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib36","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2010.04.012_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bjc.6605178","article-title":"Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis","volume":"101","author":"Koreckij","year":"2009","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2010.04.012_bib38","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1210\/me.2007-0419","article-title":"Signal transducer and activator of transcription 5b,c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells","volume":"22","author":"Fox","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejca.2010.04.012_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2005.12.164","article-title":"Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer","volume":"341","author":"Planas-Silva","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2010.04.012_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr55","article-title":"Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer","volume":"2","author":"Biscardi","year":"2000","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib41","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1093\/emboj\/20.21.6050","article-title":"PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells","volume":"20","author":"Castoria","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2010.04.012_bib42","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1158\/0008-5472.CAN-05-0912","article-title":"Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action","volume":"65","author":"Migliaccio","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib43","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1210\/me.2006-0068","article-title":"Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity","volume":"20","author":"Likhite","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejca.2010.04.012_bib44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/me.15.1.32","article-title":"Potentiation of estrogen receptor activation function 1 (AF-1) by Src\/JNK through a serine 118-independent pathway","volume":"15","author":"Feng","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejca.2010.04.012_bib45","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10549-005-9036-4","article-title":"Endocrine therapy \u2013 current benefits and limitations","volume":"93","author":"Nicholson","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.04.012_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2007.05.008","article-title":"Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells","volume":"106","author":"Yue","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejca.2010.04.012_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-005-9120-9","article-title":"Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells","volume":"97","author":"Hiscox","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.04.012_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10585-007-9065-y","article-title":"Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells","volume":"24","author":"Hiscox","year":"2007","journal-title":"Clin Exp Metastas"},{"key":"10.1016\/j.ejca.2010.04.012_bib49","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-006-0398-z","article-title":"Targeting c-Src kinase enhances tamoxifen\u2019s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins","volume":"60","author":"Planas-Silva","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2010.04.012_bib50","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-08-3127","article-title":"Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib51","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2010.04.012_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro","volume":"105","author":"Finn","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.04.012_bib53","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection","volume":"67","author":"Huang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib54","first-page":"27","article-title":"Activity of dasatinib with chemotherapy in triple-negative breast cancer cells","author":"Tryfonopoulos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2009.03.035","article-title":"Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling","volume":"283","author":"Nautiyal","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2010.04.012_bib56","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.bone.2007.12.184","article-title":"The Src inhibitor dasatinib inhibits breast cancer cell growth in vitro and exerts synergistic effects with bisphosphonates","volume":"42","author":"Journe","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ejca.2010.04.012_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.bjc.6605101","article-title":"Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells","volume":"101","author":"Pichot","year":"2009","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2010.04.012_bib58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor","volume":"23","author":"Brownlow","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2010.04.012_bib59","first-page":"173","article-title":"Evaluation of anti-osteoclastic activity of the novel, oral multi-targeted kinase inhibitor dasatinib (BMS-354825)","author":"Luo","year":"2005","journal-title":"Clin Cancer Res Suppl"},{"key":"10.1016\/j.ejca.2010.04.012_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":"Latent bone metastasis in breast cancer tied to Src-dependent survival signals","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2010.04.012_bib61","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib62","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/0008-5472.CAN-07-2661","article-title":"AXL is a potential target for therapeutic intervention in breast cancer progression","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib63","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/0008-5472.CAN-06-2027","article-title":"A Src\/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo","volume":"67","author":"Jallal","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib64","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-08-0126","article-title":"SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells","volume":"7","author":"Vultur","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.04.012_bib65","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","article-title":"N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor","volume":"49","author":"Hennequin","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2010.04.012_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","article-title":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","volume":"3","author":"Green","year":"2009","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-008-0058-6","article-title":"Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells","volume":"115","author":"Hiscox","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.04.012_bib68","article-title":"Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial","author":"Hannon","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib69","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1200\/jco.2009.27.15_suppl.1012","article-title":"Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): phase I study CA180004","volume":"27","author":"Somlo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib70","doi-asserted-by":"crossref","first-page":"242S","DOI":"10.1158\/0008-5472.SABCS-3118","article-title":"Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059","volume":"69","author":"Finn","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib71","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1200\/jco.2009.27.15_suppl.1011","article-title":"Dasatinib in advanced HER2\/neu amplified and ER\/PR-positive breast cancer: phase II study CA180088","volume":"27","author":"Mayer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib72","first-page":"S268","article-title":"Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src\/Abl kinase inhibitor, in patients with advanced breast cancer","volume":"106","author":"Campone","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.04.012_bib73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jsbmb.2005.04.004","article-title":"Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance","volume":"95","author":"Johnston","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejca.2010.04.012_bib74","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1158\/1535-7163.MCT-06-0394","article-title":"Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells","volume":"5","author":"Herynk","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.04.012_bib75","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.012_bib76","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/1078-0432.CCR-08-1507","article-title":"Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients","volume":"15","author":"Generali","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.04.012_bib77","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","article-title":"Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells","volume":"144","author":"Fei","year":"2008","journal-title":"Brit J Haematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T21:30:24Z","timestamp":1635370224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910003345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0959804910003345"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.04.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}